Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-07
2006-11-07
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S135000
Reexamination Certificate
active
07132432
ABSTRACT:
The present invention provides compounds of Formula (I):or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables L, Z0, R1, R4, R5, and R11are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.
REFERENCES:
patent: 6800776 (2004-10-01), Jong et al.
patent: 6930104 (2005-08-01), Kakihana et al.
patent: 7041693 (2006-05-01), Sheppeck
patent: 7049325 (2006-05-01), Broka et al.
patent: 7053105 (2006-05-01), Angibaud et al.
patent: 7064133 (2006-06-01), D'Angelo et al.
patent: 7074801 (2006-07-01), Yoshida et al.
Chen Lihua
Duan Jingwu
Jiang Bin
Sheppeck James
Xue Chu-Biao
Bristol--Myers Squibb Company
Lambkin Deborah C.
Sun Jing G.
LandOfFree
Hydantoin derivatives as inhibitors of tumor necrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydantoin derivatives as inhibitors of tumor necrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydantoin derivatives as inhibitors of tumor necrosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638936